Intensix, developer of a real-time predictive analytics platform for early detection of patient deterioration in the ICU and high acuity departments of hospitals, has completed a USD8.3 million Series A financing round led by Pitango Venture Capital.
The funds will be used to boost the company's sales and marketing operations in North America and to expand and accelerate the development of its predictive analytics platform.
As part of the financing Ittai Harel, managing general partner at Pitango, will join the company's board of directors.
Intensix's platform applies machine learning to provide accurate predictive clinical analytics that ICU and high-acuity staff and management can use to avoid deteriorations, save lives as well as secure operational and financial benefits. Studies to date show that the Intensix solution has the potential to improve clinical outcomes and reduce the average length of hospital stay, thereby lowering hospital treatment costs and increasing the possibility of new revenue sources.
Intensix CEO Gal Salomon says: "Predictive modelling coupled with machine learning, represents a paradigm shift in the delivery of high-acuity healthcare. Following several successful studies, we are pleased to have secured backing by high quality investors. This support will enable the company to expand and advance the capabilities of our platform and accelerate deployment in the US and EU."
Harel says: "The explosion of patient data, via electronic health records, sensors, and medical devices, provides physicians with an untapped wealth of new information. Machine learning and predictive analytics have the power to harness this data, offering great value to the healthcare industry, particularly in the area of critical care. In successive studies, Intensix has consistently demonstrated its ability to predict life-threatening deterioration and we are pleased to back them as they work to substantially improve patient outcomes.”
